Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$3.73
-$0.02(-0.92%)
At close: 4:00 PM EST
$3.73
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $4.03
Previous CloseN/A
Volume1.55M
Average Volume (3M)6.53M
Market Cap
$891.71M
Enterprise Value$1.04B
Total Cash (Recent Filing)$92.45M
Total Debt (Recent Filing)$600.99M
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Feb 24, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding239,063,430
10 Day Avg. Volume6,583,894
30 Day Avg. Volume6,534,519
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda-37.95
Forecast
1Y Price Target
$7.29Price Target Upside95.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExclusivityEsperion announced a settlement agreement with Dr. Reddy’s Laboratories, securing market exclusivity for NEXLETOL and NEXLIZET in the U.S. until April 19, 2040.
New Market EntryThe entry into the Japanese market, one of the top three global markets for cardiovascular prevention, represents a major step forward for Esperion.
Regulatory ApprovalsRegulatory approval in Japan marks a key milestone in commercial expansion, allowing Otsuka Pharmaceuticals to market NEXLETOL for hypercholesterolemia treatment.
Bears Say
Competitive RisksThe rapidly expanding competitive landscape suggests bempedoic acid may have more of a niche role.
Financial PerformanceEsperion announced 3Q25 financial results, posting EPS of ($0.16), compared to our estimate of ($0.11), and consensus of ($0.08).
Sales PerformanceU.S. Nexletol/Nexlizet sales came short of expectations due to one-time charges related to new Medicare coverage.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $4.03 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $891.71M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Feb 24, 2026 which is in 78 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.082.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is 0.3.
How many shares outstanding does Esperion have?
Esperion has 239,063,430 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went down -14.966%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.29 (95.44% Upside)
$7.29 (95.44% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.89%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth, successful strategic initiatives, and international expansion. However, increased operating expenses and onetime financial impacts were noted as challenges. Overall, the highlights of growth and strategic progress outweigh the lowlights.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$7.29
▲(95.44% Upside)
Technical Analysis
Ownership Overview
1.32% Insiders
9.21% Mutual Funds
14.39% Other Institutional Investors
66.81% Public Companies and
Individual Investors